<DOC>
	<DOCNO>NCT02941042</DOCNO>
	<brief_summary>Trial Investigating Safety , Tolerability Pharmacokinetics Single Doses NNC9204-1177 Subjects Overweight Obesity</brief_summary>
	<brief_title>A First Human Dose Trial Investigating Safety , Tolerability Pharmacokinetics Single Doses NNC9204-1177 Subjects Being Overweight With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<criteria>Male , age 1855 year ( inclusive ) time sign informed consent Body mass index ( BMI ) 25.0 34.9 kg/m^2 ( inclusive ) screen Any disorder investigator 's opinion might jeopardise subject 's safety , evaluation result , compliance protocol Subjects , age least 40 year , estimate 10year atherosclerotic cardiovascular disease ( ASCVD ) ( described American College Cardiology American Heart Association Prevention Guideline ) risk equal 5 % Male subject sexually abstinent surgically sterilise ( vasectomy ) sexually active female partner ( ) use highly effective method contraception ( condom spermicide ) combine highly effective method contraception nonpregnant female partner ( ) ( Pearl Index 1 % , implant , injectables , oral contraceptive , intrauterine device , diaphragm cervical cap+spermicide ) , and/or intend donate sperm period screen 3 month follow administration investigational medical product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>